Postoperative serum CA19-9, YKL-40, CRP and IL-6 in combination with CEA as prognostic markers for recurrence and survival in colorectal cancer

References

• Labianca R, Nordlinger B, Beretta GD, et al. Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(6):vi64–vi72.
   PubMed Web of Science ®Google Scholar
• Kopetz S, Chang GJ, Overman MJ, et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol. 2009;27(22):3677–3683.
   PubMed Web of Science ®Google Scholar
• Benson AB, Venook A, Al-Hawary MM, et al. NCCN guidelines for rectal cancer. NCCN Guidelines. 2020 Version 4. 2020 [cited 2020 Jun 3].
   Google Scholar
• Benson AB, Venook A, Al-Hawary MM, et al. NCCN guidelines for colon cancer. NCCN Guidelines. 2020 Version 3. 2020 [cited 2020 Jun 3].
   Google Scholar
• Tie J, Wang Y, Tomasetti C, et al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci Transl Med. 2016;8(346):346ra92.
   PubMed Web of Science ®Google Scholar
• Duffy MJ, van Dalen A, Haglund C, et al. Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. Eur J Cancer. 2007;43(9):1348–1360.
   PubMed Web of Science ®Google Scholar
• Locker GY, Hamilton S, Harris J, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol. 2006;24(33):5313–5327.
   PubMed Web of Science ®Google Scholar
• Sorensen CG, Karlsson WK, Pommergaard HC, et al. The diagnostic accuracy of carcinoembryonic antigen to detect colorectal cancer recurrence – a systematic review. Int J Surg. 2016;25:134–144.
   PubMed Web of Science ®Google Scholar
• Lin JK, Lin CC, Yang SH, et al. Early postoperative CEA level is a better prognostic indicator than is preoperative CEA level in predicting prognosis of patients with curable colorectal cancer. Int J Colorectal Dis. 2011;26(9):1135–1141.
   PubMed Web of Science ®Google Scholar
• Konishi T, Shimada Y, Hsu M, et al. Association of preoperative and postoperative serum carcinoembryonic antigen and colon cancer outcome. JAMA Oncol. 2018;4(3):309–315.
   PubMed Web of Science ®Google Scholar
• Scara S, Bottoni P, Scatena R. CA 19-9: biochemical and clinical aspects. Adv Exp Med Biol. 2015;867:247–260.
   PubMed Web of Science ®Google Scholar
• Terzić J, Grivennikov S, Karin E, et al. Inflammation and Colon Cancer. Gastroenterology. 2010;138(6):2101.e5–2114.e5.
   Web of Science ®Google Scholar
• Johansen JS. Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and cancer. Dan Med Bull. 2006;53(2):172–209.
   PubMed Web of Science ®Google Scholar
• Yeo IJ, Lee CK, Han SB, et al. Roles of chitinase 3-like 1 in the development of cancer, neurodegenerative diseases, and inflammatory diseases. Pharmacol Ther. 2019;203:107394.
   PubMed Web of Science ®Google Scholar
• Shrotriya S, Walsh D, Nowacki AS, et al. Serum C-reactive protein is an important and powerful prognostic biomarker in most adult solid tumors. PLoS One. 2018;13(8):e0202555.
   PubMed Web of Science ®Google Scholar
• Kersten C, Louhimo J, Ålgars A, et al. Increased C-reactive protein implies a poorer stage-specific prognosis in colon cancer. Acta Oncol. 2013;52(8):1691–1698.
   PubMed Web of Science ®Google Scholar
• Bojesen SE, Johansen JS, Nordestgaard BG. Plasma YKL-40 levels in healthy subjects from the general population. Clin Chim Acta. 2011;412(9–10):709–712.
   PubMed Web of Science ®Google Scholar
• Waldner MJ, Foersch S, Neurath MF. Interleukin-6-a key regulator of colorectal cancer development. Int J Biol Sci. 2012;8(9):1248–1253.
   PubMed Web of Science ®Google Scholar
• Osterlund P, Ruotsalainen T, Korpela R, et al. Lactobacillus supplementation for diarrhoea related to chemotherapy of colorectal cancer: a randomised study. Br J Cancer. 2007;97(8):1028–1034.
   PubMed Web of Science ®Google Scholar
• Knudsen LS, Christensen IJ, Lottenburger T, et al. Pre-analytical and biological variability in circulating interleukin 6 in healthy subjects and patients with rheumatoid arthritis. Biomarkers. 2008;13(1):59–78.
   PubMed Web of Science ®Google Scholar
• Davison AC, Hinkley DV. Bootstrap methods and their applications. Cambridge (UK): Cambridge University Press; 1997.
   Google Scholar
• Compton C, Fenoglio-Preiser CM, Pettigrew N, et al. American Joint Committee on Cancer Prognostic Factors Consensus Conference: Colorectal Working Group. Cancer. 2000;88(7):1739–1757.
   PubMed Web of Science ®Google Scholar
• Thirunavukarasu P, Sukumar S, Sathaiah M, et al. C-stage in colon cancer: implications of carcinoembryonic antigen biomarker in staging, prognosis, and management. J Natl Cancer Inst. 2011;103(8):689–697.
   PubMedGoogle Scholar
• Shinkins B, Nicholson BD, James T, et al. What carcinoembryonic antigen level should trigger further investigation during colorectal cancer follow-up? A systematic review and secondary analysis of a randomised controlled trial. Health Technol Assess. 2017;21(22):1–60.
   Web of Science ®Google Scholar
• Yavorkovsky LL, Kwong MS, Jhatakia S, et al. Unrecognized value of carcinoembryonic antigen in recurrent rectal and sigmoid colon cancer: case series. Perm J. 2019;23. DOI:10.7812/TPP/18-022
   PubMedGoogle Scholar
• Nicholson BD, Shinkins B, Pathiraja I, et al. Blood CEA levels for detecting recurrent colorectal cancer. Cochrane Database Syst Rev. 2015;12:Cd011134.
   Google Scholar
• Vukobrat-Bijedic Z, Husic-Selimovic A, Sofic A, et al. Cancer antigens (CEA and CA 19-9) as markers of advanced stage of colorectal carcinoma. Med Arh. 2013;67(6):397–401.
   Google Scholar
• Shin JK, Kim HC, Lee WY, et al. High preoperative serum CA 19-9 levels can predict poor oncologic outcomes in colorectal cancer patients on propensity score analysis. Ann Surg Treat Res. 2019;96(3):107–115.
   PubMed Web of Science ®Google Scholar
• Shibutani M, Maeda K, Nagahara H, et al. Significance of CEA and CA19-9 combination as a prognostic indicator and for recurrence monitoring in patients with stage II colorectal cancer. Anticancer Res. 2014;34(7):3753–3758.
   PubMed Web of Science ®Google Scholar
• Zhou W, Yang F, Peng J, et al. High pretreatment serum CA19-9 level predicts a poor prognosis for patients with stage III colon cancer after curative resection and adjuvant chemotherapy. J Cancer. 2019;10(16):3810–3818.
   PubMed Web of Science ®Google Scholar
• Ryuk JP, Choi GS, Park JS, et al. Predictive factors and the prognosis of recurrence of colorectal cancer within 2 years after curative resection. Ann Surg Treat Res. 2014;86(3):143–151.
   PubMed Web of Science ®Google Scholar
• Park IJ, Choi GS, Jun SH. Prognostic value of serum tumor antigen CA19-9 after curative resection of colorectal cancer. Anticancer Res. 2009;29(10):4303–4308.
   PubMed Web of Science ®Google Scholar
• Abe S, Kawai K, Ishihara S, et al. Prognostic impact of carcinoembryonic antigen and carbohydrate antigen 19-9 in stage IV colorectal cancer patients after R0 resection. J Surg Res. 2016;205(2):384–392.
   PubMed Web of Science ®Google Scholar
• Cintin C, Johansen JS, Christensen IJ, et al. High serum YKL-40 level after surgery for colorectal carcinoma is related to short survival. Cancer. 2002;95(2):267–274.
   PubMed Web of Science ®Google Scholar
• Ye HM, Lu YZ, Liang XM, et al. Clinical significance of combined testing of YKL-40 with CEA in Chinese colorectal cancer patients. Clin Lab. 2014;60(3):397–405.
   PubMed Web of Science ®Google Scholar
• Johansen JS, Christensen IJ, Jorgensen LN, et al. Serum YKL-40 in risk assessment for colorectal cancer: a prospective study of 4,496 subjects at risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2015;24(3):621–626.
   PubMed Web of Science ®Google Scholar
• Fuksiewicz M, Kotowicz B, Rutkowski A, et al. The assessment of clinical usage and prognostic value of YKL-40 serum levels in patients with rectal cancer without distant metastasis. Technol Cancer Res Treat. 2018;17. DOI:10.1177/1533033818765209
   PubMed Web of Science ®Google Scholar
• Tarpgaard LS, Guren TK, Glimelius B, et al. Plasma YKL-40 in patients with metastatic colorectal cancer treated with first line oxaliplatin-based regimen with or without cetuximab: results from the NORDIC VII Study. PLoS One. 2014;9(2):e87746.
   PubMed Web of Science ®Google Scholar
• Peltonen R, Gramkow MH. Elevated serum YKL-40, IL-6, CRP, CEA, and CA19-9 combined as a prognostic biomarker panel after resection of colorectal liver metastases. PLOS One. 2020.
   Google Scholar
• Guo YZ, Pan L, Du CJ, et al. Association between C-reactive protein and risk of cancer: a meta-analysis of prospective cohort studies. Asian Pac J Cancer Prev. 2013;14(1):243–248.
   PubMedGoogle Scholar
• Matsubara D, Arita T, Nakanishi M, et al. The impact of postoperative inflammation on recurrence in patients with colorectal cancer. Int J Clin Oncol. 2020;25(4):602–613.
   PubMed Web of Science ®Google Scholar
• Yamamoto M, Saito H, Uejima C, et al. Prognostic value of the combination of pre- and postoperative C-reactive protein in colorectal cancer patients. Surg Today. 2018;48(11):986–993.
   PubMed Web of Science ®Google Scholar
• Vainer N, Dehlendorff C, Johansen JS. Systematic literature review of IL-6 as a biomarker or treatment target in patients with gastric, bile duct, pancreatic and colorectal cancer. Oncotarget. 2018;9(51):29820–29841.
   PubMedGoogle Scholar
• Shiga K, Hara M, Nagasaki T, et al. Preoperative serum interleukin-6Is a potential prognostic factor for colorectal cancer, including stage II patients. Gastroenterol Res Pract. 2016;2016:9701574.
   PubMed Web of Science ®Google Scholar
• Aubin JM, Bressan AK, Grondin SC, et al. Assessing resectability of colorectal liver metastases: how do different subspecialties interpret the same data? Can J Surg. 2018;61(4):251–256.
   PubMed Web of Science ®Google Scholar
• Spindler BA, Bergquist JR, Thiels CA, et al. Incorporation of CEA improves risk stratification in stage II colon cancer. J Gastrointest Surg. 2017;21(5):770–777.
   PubMed Web of Science ®Google Scholar
• Auclin E, Andre T, Taieb J, et al. Association of post-operative CEA with survival and oxaliplatin benefit in patients with stage II colon cancer: a post hoc analysis of the MOSAIC trial. Br J Cancer. 2019;121(4):312–317.
   PubMed Web of Science ®Google Scholar